Human Dopaminergic Progenitor Cells

BIOLOGICAL5 trials

Sponsors

iRegene Therapeutics Co., Ltd.

Conditions

Early-onset Parkinson's DiseaseMultiple System Atrophy - Parkinsonian Subtype (MSA-P)Parkinson DiseaseParkinson Disease (PD)

Phase 1

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

RecruitingNCT06167681

iRegene Therapeutics Co., Ltd.Parkinson Disease

Start: 2024-01-17End: 2029-07-31Target: 40Updated: 2024-11-01

The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

RecruitingNCT06608355

iRegene Therapeutics Co., Ltd.Early-onset Parkinson's Disease

Start: 2024-08-23End: 2027-03-31Target: 6Updated: 2024-11-07

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

RecruitingNCT07102342

iRegene Therapeutics Co., Ltd.Parkinson Disease

Start: 2026-01-12End: 2032-09-01Target: 5Updated: 2026-05-11

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

RecruitingNCT07289477

iRegene Therapeutics Co., Ltd.Multiple System Atrophy - Parkinsonian Subtype (MSA-P)

Start: 2026-01-05End: 2031-07-01Target: 9Updated: 2026-04-14

Phase 2

The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

Not yet recruitingNCT07028632

iRegene Therapeutics Co., Ltd.Parkinson Disease (PD)

Start: 2025-06-30End: 2030-12-31Target: 30Updated: 2025-06-29